Oryzon Genomics, S.A. announced that Dr. Tamara Maes will be retiring as a Chief Scientific Officer at Oryzon in 2020. The highly experienced Dr. Torsten Hoffmann, who has spent more than 23 years in pharmaceutical research and development including senior roles at Roche and Danish biotech Zealand Pharma, is appointed as Oryzon’s new CSO to lead all R&D efforts of the company, effective November 2nd. Dr. Maes will personally lead the transition for the next 90 days and will continue as VP of the Board of Directors of Oryzon and as President of its Scientific Advisory Board. The Company’s clinical development strategy continues unchanged. At Roche, Dr. Hoffmann was Head of Discovery Chemistry and Head of the Roche Postdoc Fellowship Program. Subsequently he served as Chief Scientific Officer and Executive VP at Zealand Pharma, Chief Scientific Officer of British Silence Therapeutics and most recently SVP Drug Discovery at Taros Chemicals in Germany. Dr. Hoffmann invented Netupitant, approved in the U.S. as Akynzeo® for chemotherapy-induced nausea and vomiting, and has held several Scientific Advisory Board member roles in the European biotechnology industry.